Characterization of Neurological Biomarkers in Patients with Early Relapsing Multiple Sclerosis and Comparison to Healthy Controls: Year 1 Interim Analysis of the ENLIGHTEN Study of Ozanimod (P6-1.009)
Evaluate the effect of 1 year of ozanimod on biomarkers of axonal and astrocytic damage in patients with early relapsing multiple sclerosis (RMS) and compare biomarker concentrations in patients with RMS vs healthy controls.
Authors
- Lauren P. Shapiro
- Sarah A. Morrow (ORCID: https://orcid.org/0000-0001-7522-6440)
- Antonin Bal (ORCID: https://orcid.org/0000-0002-0261-2495)
- Jon Riolo
- Sarah Harris (ORCID: https://orcid.org/0000-0002-1265-4453)
Institutions
- Western University (CA)
- Bristol-Myers Squibb (Germany) (DE)
- University of Calgary (CA)
- London Health Sciences Centre (CA)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208996
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00